{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Complete response will be assessed according to RECIST criteria","groups":[{"description":"Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3","id":"OG000","title":"HAART"},{"description":"Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3","id":"OG001","title":"HAART+ Bevacizumab Injection"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Number of Participants With Complete Response","type":"PRIMARY","unitOfMeasure":"participants"}